Safety and Efficacy of Selinexor Sequential Azacytidine in Newly Diagnosed Patients with Myelodysplastic Syndromes EB1 or EB2: A Single-Center, Single-Arm, Phase Ib/II Trial

• Published in: Blood Vol. 142; no. Supplement 1; p. 1856
• Main Authors: Ma, Liya, Yang, Wenli, Zhou, Xinping, Ye, Li, Xu, Gaixiang, Hu, Chao, Luo, Yingwan, Yang, Chunmei, Ge, Zheng, Tong, Hongyan
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 02.11.2023

Background: Azacytidine is one of the hypomethylating agents (HMAs) for the treatment of higher-risk myelodysplastic syndromes (MDS). However, clinical outcomes of patients treated with azacytidine monotherapy were far from satisfactory with overall response rate (ORR) of 41%-59% and overall surviva...